Free Trial
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

$0.28
+0.00 (+0.07%)
(As of 12:33 PM ET)
Today's Range
$0.27
$0.29
50-Day Range
$0.26
$3.18
52-Week Range
$0.26
$3.53
Volume
695,038 shs
Average Volume
1.14 million shs
Market Capitalization
$18.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

GlycoMimetics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
3,484.2% Upside
$10.00 Price Target
Short Interest
Bearish
9.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.00mentions of GlycoMimetics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to ($0.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

206th out of 921 stocks

Pharmaceutical Preparations Industry

82nd out of 426 stocks

GLYC stock logo

About GlycoMimetics Stock (NASDAQ:GLYC)

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GLYC Stock Price History

GLYC Stock News Headlines

Why Is GlycoMimetics Stock Falling In Pre-market?
GlycoMimetics, Inc. (GLYC)
GlycoMimetics Inc
Q4 2023 GlycoMimetics Inc Earnings Call
GlycoMimetics: Q4 Earnings Snapshot
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2024
Today
5/23/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLYC
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+3,484.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-36,900,000.00
Pretax Margin
-372,770.03%

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$0.45 per share

Miscellaneous

Free Float
58,856,000
Market Cap
$17.98 million
Optionable
Optionable
Beta
2.30
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Harout Semerjian (Age 54)
    CEO, President & Director
    Comp: $1.13M
  • Ms. Rachel K. King (Age 65)
    Co-Founder & Director
    Comp: $40k
  • Mr. Brian M. Hahn (Age 50)
    Senior VP & CFO
    Comp: $822.12k
  • Dr. Edwin Rock M.D. (Age 63)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $677.4k
  • Ms. Stephanie R. Irish CPA (Age 53)
    Vice President of Accounting
  • Mr. Christian B. Dinneen-Long
    General Counsel & Company Secretary
  • Mr. Bruce Johnson (Age 56)
    Senior VP & Chief Commercial Officer
  • Mr. Chinmaya Rath (Age 47)
    Senior VP & Chief Business Officer
  • Mr. Shantha Tyavanagimatt Ph.D.
    Senior Vice President of Technical Operations

GLYC Stock Analysis - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLYC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLYC, but not buy additional shares or sell existing shares.
View GLYC analyst ratings
or view top-rated stocks.

What is GlycoMimetics' stock price target for 2024?

2 brokerages have issued twelve-month price objectives for GlycoMimetics' stock. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 3,484.2% from the stock's current price.
View analysts price targets for GLYC
or view top-rated stocks among Wall Street analysts.

How have GLYC shares performed in 2024?

GlycoMimetics' stock was trading at $2.36 at the start of the year. Since then, GLYC stock has decreased by 88.2% and is now trading at $0.2790.
View the best growth stocks for 2024 here
.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our GLYC earnings forecast
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings data on Wednesday, March, 27th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The biotechnology company had revenue of $0.01 million for the quarter.

What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (5.95%), Vanguard Group Inc. (4.29%), Acadian Asset Management LLC (0.51%), Ikarian Capital LLC (0.00%), Affinity Asset Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell.
View institutional ownership trends
.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLYC) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners